BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SenzaGen - ECPv6.18.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://senzagen.com
X-WR-CALDESC:Events for SenzaGen
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210930
DTEND;VALUE=DATE:20211005
DTSTAMP:20210930T105113Z
CREATED:20210408T090913Z
LAST-MODIFIED:20210930T105113Z
UID:26194-1632960000-1633391999@senzagen.com
SUMMARY:Eurotox
DESCRIPTION:Eurotox 2021 Virtual Congress\n27 September – 1 October\n  \n\n\n\n\n🌎Industry symposium hosted by SenzaGen \nSep 29\, 17.30 – 18.30\n\n\n\n\n\nFilling data gaps in skin sensitization testing: in vitro hazard and potency assessments using GARD \n\nDr Andy Forreryd \nDr Henrik Johansson\n\n\n\n\nGARDskin and GARDpotency: a proof of concept study to investigate the applicability domain for agrochemical formulations \n\nGuest Speaker\nMarco​ Corvaro\, Corteva Agriscience\n\n\n\n\n\nAssessment of the skin sensitizing potential of pandemic-associated medical devices using the GARDskin Medical Device assay \n\nGuest Speaker\nPeter Mohlin\, Essity Hygiene & Health AB\n\n\n\n\n\n\n\n  \n \n🌎Presentation at Session 12 – Symposium\nSep 28\, 16.30 – 18.30\n\n\n\n\n\nGenomics-based platforms in combination with machine learning algorithms enabling well informed and reliable risk assessments for different toxicological endpoints \nSession 12– Symposium: Application of high throughput transcriptomics in mechanism-based chemical safety assessment\nDr Andy Forreryd\n\n\n\n\n\n\n\n\nPosters open for viewing: \n Sep 27 – Oct 1\n\n\n\n# P23-11 \nAbstract ID 140\nQuantitative sensitizing potency assessment using GARDskin Dose-Response\nDr Henrik Johansson\n\n\n# P04-10 \nAbstract ID 164\nApplicability domain of the GARDskin Medical Device test for in vitro skin sensitization testing of medical devices\nDr Rose-Marie Jenvert \n \n\n\n# P04-30 \nAbstract ID 390\nIn vitro assessment of the skin sensitizing potential and potency of epoxy resin monomers and pre-polymer mixtures using the GARD assay\nDr Helge Gehrke\, Eurofins\n\n\n# P23-34 \nAbstract ID 402\nAssessment of the skin sensitizing potential of pandemic-associated medical devices using the GARDskin Medical Device assay\nPeter Mohlin\, Essity
URL:https://senzagen.com/event/eurotox-2/
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2021/04/eurotox2021.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211013
DTEND;VALUE=DATE:20211015
DTSTAMP:20210906T082248Z
CREATED:20210826T115835Z
LAST-MODIFIED:20210906T082248Z
UID:27465-1634083200-1634255999@senzagen.com
SUMMARY:Cosmetic 360
DESCRIPTION:The international innovation fair for cosmetic and perfume industry\nOctober 13-14 | Carrousel du Louvre\, Paris | Booth: S4\nMeet SenzaGen and partners PKDerm\, GenEvolutioN\, WatchFrog and CEHTRA at Cosmetic 360\, the international innovation fair for the cosmetic and perfume industry\, to find out about our latest innovations for safety and efficacy evaluation of cosmetics and ingredients. \nOrganised by Cosmetic Valley\, this event will bring together the Cosmetic 360 international trade fair and the annual summit of the French fragrance and cosmetics industry. \n  \n \nBenefit from our joint expertise\nWe look forward to meeting you to discuss our common interests and possible collaboration on safety testing of cosmetics:\n  \n\nSensitization\nIrritation\nPhoto irritation/sensitization\nEndocrine disruptor properties\nDermal absorption\nMOS toxicology risk assessment\nGenotoxicity\n\n  \n \n\n 
URL:https://senzagen.com/event/cosmetic-360/
LOCATION:Paris\, France
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2021/08/stand_carre_en_4ef9da3d597eb6431934405e8189f76207d8ad64.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20211013T160000
DTEND;TZID=Europe/Stockholm:20211013T170000
DTSTAMP:20210906T123106Z
CREATED:20210906T094522Z
LAST-MODIFIED:20210906T123106Z
UID:27554-1634140800-1634144400@senzagen.com
SUMMARY:Webinar: Safer Medical Devices – In Vitro Assays As Part of a Biological Evaluation
DESCRIPTION:In this webinar\, the speakers will discuss the uses of in vitro assays as a part of the risk assessment and biological evaluation for the following endpoints: cytotoxicity\, skin irritation and skin sensitization. \nKey topics\nThe presentation will introduce biological evaluation and biocompatibility testing of medical devices\, with focus on in vitro assays for skin irritation and skin sensitization now implemented in the ISO 10993-23:2021 and ISO/FDIS 10993-10:2021. For assessment of skin sensitization\, the GARD™-technology will be introduced and the speakers will discuss how it can be used as a part of a biological evaluation. \nThe webinar will conclude with customer cases where in vitro assays\, including GARDskin Medical Device assay and GARDskin Dose-Response\, have been successfully utilized for risk assessment as part of the biological evaluation and for risk-based decision-making in compliance with the principles of the 3Rs throughout the product life cycle. \n  \n \nSpeakers\n  \n\nA highly accurate and ethical alternative \nAn exciting evolution is ongoing in the medical device toxicology field\, transitioning from a process that largely relied on the results of animal testing to one which is increasingly focused on the use of in vitro methods for the safety assessment of medical device materials. A big step towards replacing animal testing for medical devices was taken when in vitro skin irritation testing using Reconstructed human Epidermis (RhE) tissue was implemented in the ISO 10993-23 standard published earlier this year. Moreover\, in vitro assays for skin sensitization have been included in the updated ISO 10993-10. \nIn vitro biocompatibility package \nThe in vitro biocompatibility package includes testing of the three endpoints that need to be evaluated for all medical device products: cytotoxicity\, skin irritation and skin sensitization\, offering a solution for customers looking for a highly accurate and ethical alternative for testing of materials and medical devices. \nCytotoxicity \nThe endpoint cytotoxicity can be tested in vitro using qualitative and quantitative test methods as described in ISO 10993-5:2009 and have a history of use both for regulatory purposes and as a screening tool early in the product development phase. \nSkin irritation \nThe endpoint skin irritation using RhE-tissue according to ISO 10993-23:2021 provides human relevant results with higher accuracy and less false positive results compared to the rabbit model. \nSkin sensitization with GARD™ \nThe endpoint skin sensitization can be assessed in vitro using the GARDskin Medical Device assay\, based on a state-of-the-art technology GARD; including human immunological cells\, a specific genomic biomarker signature and a machine learning-assisted classification-model. The GARDskin Medical Device assay enables the medical device industry to perform in vitro skin sensitization testing of both saline and oil extracts from devices or materials as described in ISO 10993-12 and FDIS/ISO 10993-10:2021\, thus mimicking the intended use of the device when in contact with skin. \n\nRegister now
URL:https://senzagen.com/event/webinar-safer-medical-devices-in-vitro-assays-as-part-of-a-biological-evaluation/
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2021/09/Banner-2.jpg
END:VEVENT
END:VCALENDAR